Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research industries. The company sells its products through its direct sales force in the United States; and a network of independent distributors and strategic partners internationally. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Phone353-1276-9800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$99.14 million
Profitability
Miscellaneous
Employees556
OptionableOptionable
Trinity Biotech (NASDAQ:TRIB) Frequently Asked Questions
What is Trinity Biotech's stock symbol?
Trinity Biotech trades on the NASDAQ under the ticker symbol "TRIB."
How were Trinity Biotech's earnings last quarter?
Trinity Biotech plc (NASDAQ:TRIB) announced its quarterly earnings results on Tuesday, October, 23rd. The company reported $0.05 EPS for the quarter, missing the Zacks' consensus estimate of $0.06 by $0.01. The business had revenue of $23.71 million for the quarter. Trinity Biotech had a negative net margin of 42.24% and a positive return on equity of 3.74%. View Trinity Biotech's Earnings History.
When is Trinity Biotech's next earnings date?
Has Trinity Biotech been receiving favorable news coverage?
Headlines about TRIB stock have trended somewhat positive on Friday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Trinity Biotech earned a news sentiment score of 1.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future.
Who are some of Trinity Biotech's key competitors?
Some companies that are related to Trinity Biotech include Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Celldex Therapeutics (CLDX), Vermillion (VRML), ImmuCell (ICCC), Riot Blockchain (RIOT), Achieve Life Sciences (ACHV), Akers Biosciences (AKER), GeneNews (GNWSF), Arca Biopharma (ABIO), Fluoropharma Medical (FPMI), BG Medicine (BGMD) and Response Genetics (RGDXQ).
Who are Trinity Biotech's key executives?
Trinity Biotech's management team includes the folowing people:
- Mr. Ronan O'Caoimh, Co-Founder, Chairman & CEO (Age 63)
- Mr. Kevin Tansley, CFO, Company Sec. & Exec. Director (Age 48)
- Dr. James Walsh, Exec. Director (Age 61)
Who are Trinity Biotech's major shareholders?
Trinity Biotech's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Paradice Investment Management LLC (6.59%), First Wilshire Securities Management Inc. (4.12%), Hunter Associates Investment Management LLC (4.05%), Boston Partners (2.27%), Millennium Management LLC (0.65%) and BlackRock Inc. (0.26%).
Which institutional investors are selling Trinity Biotech stock?
TRIB stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, Paradice Investment Management LLC, First Wilshire Securities Management Inc., Millennium Management LLC, Two Sigma Investments LP and Wedbush Securities Inc..
Which institutional investors are buying Trinity Biotech stock?
TRIB stock was purchased by a variety of institutional investors in the last quarter, including Hunter Associates Investment Management LLC and BlackRock Inc..
How do I buy shares of Trinity Biotech?
Shares of TRIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Trinity Biotech's stock price today?
One share of TRIB stock can currently be purchased for approximately $2.60.
How big of a company is Trinity Biotech?
Trinity Biotech has a market capitalization of $62.51 million and generates $99.14 million in revenue each year. Trinity Biotech employs 556 workers across the globe.
What is Trinity Biotech's official website?
How can I contact Trinity Biotech?
Trinity Biotech's mailing address is IDA BUSINESS PARK BRAY, WICKLOW L2, . The company can be reached via phone at 353-1276-9800 or via email at [email protected]
MarketBeat Community Rating for Trinity Biotech (NASDAQ TRIB)
MarketBeat's community ratings are surveys of what our community members think about Trinity Biotech and other stocks. Vote "Outperform" if you believe TRIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
